CD5-L829-tLNP CD8+ Cell Targeted Antibody-Conjugated Premade EGFP mRNA Lipid Nanoparticle
 
The CD5-L829-tLNP CD8+ Cell Targeted Antibody-Conjugated Premade mRNA-LNP is a cutting-edge targeted delivery system designed for the precise, in vivo transfection of CD8+ T cells. This advanced formulation integrates the specificity of anti-human CD8 antibodies with the superior delivery capabilities of CICL1 (L829), a novel ionizable cationic lipid engineered to overcome the limitations of conventional lipid nanoparticles.
 
Unlike standard formulations that often accumulate in the liver, this tLNP system is optimized to reduce off-target hepatic delivery significantly. By covalently conjugating anti-CD8 antibodies to the LNP surface and utilizing the proprietary A-11 CICL1 lipid, this product enables the direct engineering of functional CAR T cells within the organism. It offers a scalable, off-the-shelf solution for researchers investigating oncology and autoimmune therapies without the need for complex ex vivo manufacturing or lymphodepleting chemotherapy.
 
Key Features
Novel Ionizable Lipid (CICL1/L829): Specifically engineered for targeted LNPs, L829 demonstrates enhanced biodegradability and rapid clearance compared to benchmark lipids like ALC-0315.
Precision Targeting: Surface-conjugated anti-human CD8 antibodies ensure preferential transfection of CD8+ T cells over other immune subsets.
Reduced Liver Accumulation: The formulation is designed to minimize off-target delivery to the liver, improving the safety profile in rodent and primate models.
High-Efficiency Transfection: Capable of generating functional anti-CD19 or anti-CD20 CAR T cells directly in vivo, leading to rapid and deep B-cell depletion in preclinical models.
Ready-to-Use: Premade with fully modified mRNA, simplifying the workflow for complex gene editing and immunotherapy research.
 
Applications
In Vivo CAR T Cell Generation: Development of therapies for oncology and autoimmune diseases by engineering T cells directly within the host.
B-Cell Depletion Studies: Investigation of immune reset mechanisms through the rapid elimination of B cells and subsequent repopulation with naïve phenotypes.
Gene Editing: Delivery of mRNA payloads (e.g., Cas9, base editors) specifically to cytotoxic T cells.
Immunotherapy Optimization: Screening of mRNA constructs and antibody targeting efficiency in a controlled, targeted manner.
 
Product Specifications
Product Name: CD5-L829-tLNP CD8+ Cell Targeted Antibody-Conjugated Premade mRNA-LNP w. A-11 CICL1
Lipid Composition: Features proprietary A-11 CICL1 (L829) ionizable lipid.
Targeting Moiety: Covalently conjugated anti-human CD8 antibody.
Payload: Fully modified mRNA (specific reporter or functional cargo as selected).
Formulation: Sterile, suspended in physiological buffer.
Reference: Hunter TL, June CH, Aghajanian H et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025 Jun 19;388(6753):1311-1317.
 
Product Specifications
Parameter
Specification
Payload
EGFP mRNA (m1Ψ)
Conjugated Antibody
mAb
Ionizable Lipid
A-11 CICL-1 (L829)
Formulation Components
Ionizable lipid, DSPC, PEG-2000 DMG, Cholesterol
Storage Buffer
10% Sucrose in TBS
Appearance
Clear and colorless
Concentration
Batch specific (~0.1 mg/mL)
Availability
On-demand 
 
Storage & Handling Instructions
Storage Temperature: Store at 4°C immediately upon receipt
Shipping: Product is shipped on ice packs to maintain cold chain integrity
Handling Precautions:
Avoid freeze-thaw cycles to maintain nanoparticle integrity
Handle gently to prevent aggregation
Use sterile technique when aliquoting or diluting
Protect from prolonged exposure to room temperature
Keep away from light to preserve mRNA stability
Stability: When stored properly at 4°C, the product maintains stability for 6 months from the date of manufacture. For optimal performance, use within the specified timeframe.
 
Custom Solutions
At PreciGenome, we understand that research requirements vary. We offer comprehensive customization options for this product:
Alternative Targeting Antibodies: Custom antibody conjugation for different cell surface markers
Payload Modifications: Alternative mRNA sequences, reporters, or therapeutic genes
Formulation Adjustments: Modified lipid compositions or concentrations
Scale Options: Various volume and concentration specifications
Buffer Systems: Alternative storage and working buffers
Bulk Manufacturing: Large-scale production for extensive studies
Our technical team works closely with researchers to develop tailored solutions that meet specific experimental needs and research objectives.
 
Important Notes
For Research Use Only. This product is not for human or veterinary use.
For technical support, custom formulations, or bulk orders, please contact us.
This product contains genetically modified materials and should be handled according to institutional biosafety guidelines
Performance may vary depending on cell type, experimental conditions, and handling procedures
Optimal transfection conditions should be determined empirically for each specific application
Product specifications are subject to batch-specific variations; refer to individual Certificate of Analysis
Users should validate targeting efficiency and expression levels in their specific experimental systems